These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 2291602)

  • 1. [Working hypothesis for the effect of GABAergic, glycinergic or glutamatergic drugs in the treatment of Parkinson disease].
    Vamvakidès A
    Ann Pharm Fr; 1990; 48(2):70-80. PubMed ID: 2291602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A hypothesis for pharmacologic research on GABAergic approaches in Huntington chorea].
    Vamvakides A
    Ann Pharm Fr; 1989; 47(5):259-65. PubMed ID: 2534675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current preclinical findings on substances against Parkinson's disease].
    Gerlach M; Riederer P
    Nervenarzt; 2003 Mar; 74 Suppl 1():S2-6. PubMed ID: 12624677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P; Tremblay L; Féger J; Hirsch EC
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy.
    Fischer PA
    J Neural Transm Suppl; 1995; 46():381-9. PubMed ID: 8821073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
    Cools R
    Neurosci Biobehav Rev; 2006; 30(1):1-23. PubMed ID: 15935475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinson's disease: drug therapy.
    Oertel WH; Quinn NP
    Baillieres Clin Neurol; 1997 Apr; 6(1):89-108. PubMed ID: 9426870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peculiarities of L: -DOPA treatment of Parkinson's disease.
    Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
    Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study.
    Merello M; Nouzeilles MI; Cammarota A; Leiguarda R
    Clin Neuropharmacol; 1999; 22(5):273-6. PubMed ID: 10516877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
    Mercuri NB; Bernardi G
    Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Problems with current pharmacologic treatment of Parkinson's disease.
    Hurtig HI
    Exp Neurol; 1997 Mar; 144(1):10-6. PubMed ID: 9126144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists.
    Pinna A; Wardas J; Simola N; Morelli M
    Life Sci; 2005 Nov; 77(26):3259-67. PubMed ID: 15979104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical pharmacology of dyskinesias induced by L-dopa in Parkinsonian patients].
    Rascol O; Brefel-Courbon C; Blin O
    Therapie; 1998; 53(1):43-8. PubMed ID: 9773099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Parkinson disease--new aspects of therapy].
    Schneider E
    Wien Med Wochenschr; 1988 Feb; 138(3):54-7. PubMed ID: 3285599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dihydroergocryptine in the treatment of Parkinson's disease.
    Bonuccelli U; D'Antonio P; D'Avino C; Piccini P; Muratorio A
    J Neural Transm Suppl; 1995; 45():239-45. PubMed ID: 8748631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioids and motor complications in Parkinson's disease.
    Samadi P; Bédard PJ; Rouillard C
    Trends Pharmacol Sci; 2006 Oct; 27(10):512-7. PubMed ID: 16908075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical aspects and conservative therapy of Parkinson disease].
    Dengler R
    Zentralbl Neurochir; 1995; 56(4):148-52. PubMed ID: 8571692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
    Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.